Cabozantinib (cabo) is an oral, potent inhibitor of MET and VEGFR2.
results:
recruiting phase II trials
From Wiki:
Positive data from clinical trials indicate cabozantinib is particularly beneficial in metastatic advanced prostate cancer. 97% of patients either had stabilization or improvement in bone malignancies. The median time to disease progression was 29 weeks.
Wow. Breast cancer trials have not gotten as good a result, but not far behind.
No comments:
Post a Comment